BriaCell stock rises on license deal for anti-cancer agent

Aug. 04, 2022 9:36 AM ETBriaCell Therapeutics Corp. (BCTX)By: Ravikash, SA News Editor
  • BriaCell Therapeutics (NASDAQ:BCTX) stock rose 5% on Aug. 4 after the company said it secured an exclusive license from University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent to treat cancer.
  • In animal models, sCD80 was well-tolerated and stopped tumor growth by potentially restoring natural anti-tumor immunity, BriaCell said in an Aug. 4 press release.
  • Under the agreement, BriaCell gains worldwide rights to develop and sell sCD80, while UMBC retains ownership of the patents.
  • BriaCell will pay royalties to UMBC upon sale of the product plus patent management costs.
  • "Based on the promising data in animal studies, we plan to explore the potential use of sCD80 technology as a therapeutic agent in combination with our other immunotherapies or on its own," said BriaCell's President and CEO Bill Williams.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.